In men with de novo metastatic castration-sensitive prostate cancer (mCSPC), the addition of abiraterone (Zytiga, Janssen) and prednisone to androgen deprivation therapy (ADT) and docetaxel significantly improved radiographic progression-free survival (rPFS), according to results from the phase 3 PEACE-1 study.
Presenting the study at the 2021 annual meeting of the American Society of Clinical Oncology (abstract 5000), investigator Karim Fizazi, MD, a medical oncologist at the Institut de